title: [Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro].
abstract: In order to evaluate the combination therapy for liver and bile tract cancer, the effects of anticancer drugs and hyperthermia were observed using cultured human cancer cell lines. In the case of gall bladder cancer cell line (NOZ), combination of adriamycin and hyperthermia showed more effective inhibition for cell proliferation than MMC + hyperthermia and 5-FU + hyperthermia. Hepatocellular carcinoma cell line (JHH-4) showed remarkable inhibition of cell growth and secretion of albumin by combination treatment of adriamycin and hyperthermia. Morphologically, JHH-4 cells were enlarged and the nucleus was also enlarged with combination adriamycin and hyperthermia by phase contrast microscopy. Cytoskeleton of JHH-4 cells became irregular and intercellular borderline was unclear by plasma polymerization replica method (PPRM). The effects of BRM (OK-432 and TNF) on HCC cell lines was also investigated. OK-432 directly inhibited proliferation of JHH-4 cells. We observed internalization of OK-432 by JHH-4 cells with TEM and 16-mm movie. TNF showed various effects on human HCC cell lines. Proliferation of two cell lines was inhibited, and one tended to be enhanced after the addition of TNF to the medium. Hyperthermia influenced the effects of TNF to HCC cell lines. We think that this paper is a very significant study for improving the therapy for hepato-biliary cancers.
authors.affiliation: First Dept. of Internal Medicine, Jikei University School of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Hasumura
authors.forename: S
authors.initials: S
authors.lastname: Nagamori
authors.forename: K
authors.initials: K
authors.lastname: Fujise
authors.forename: S
authors.initials: S
authors.lastname: Homma
authors.forename: H
authors.initials: H
authors.lastname: Sujino
authors.forename: T
authors.initials: T
authors.lastname: Matsuura
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: M
authors.initials: M
authors.lastname: Niiya
authors.forename: H
authors.initials: H
authors.lastname: Kameda
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000628:therapy*; D002460:Cell Line; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D005706:Gallbladder Neoplasms / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced; D066298:In Vitro Techniques; D008113:Liver Neoplasms / Q000188:drug therapy / Q000628:therapy*; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D010844:Picibanil / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D008937:Mitomycins; D014409:Tumor Necrosis Factor-alpha; D010844:Picibanil; D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil